Next Article in Journal
Antimicrobial Properties and Cytotoxic Effect of Imidazolium Geminis with Tunable Hydrophobicity
Next Article in Special Issue
Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment
Previous Article in Journal
An Easy Route to Aziridine Ketones and Carbinols
Previous Article in Special Issue
Ferroptosis Induction in Multiple Myeloma Cells Triggers DNA Methylation and Histone Modification Changes Associated with Cellular Senescence
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 23
10.3390/ijms222313144
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma

by
Aristea-Maria Papanota
1,†,
Paraskevi Karousi
2,†,
Christos K. Kontos
2,
Pinelopi I. Artemaki
2,
Christine-Ivy Liacos
1,
Maria-Alexandra Papadimitriou
2,
Tina Bagratuni
1,
Evangelos Eleutherakis-Papaiakovou
1,
Panagiotis Malandrakis
1,
Ioannis Ntanasis-Stathopoulos
1,
Maria Gavriatopoulou
1,
Efstathios Kastritis
1,
Margaritis Avgeris
2,3,
Meletios-Athanasios Dimopoulos
1,
Andreas Scorilas
2,* and
Evangelos Terpos
1,*
1
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
2
Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15701 Athens, Greece
3
Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, “P. & A. Kyriakou” Children’s Hospital, 11527 Athens, Greece
*
Authors to whom correspondence should be addressed.
†
A.-M.P. and P.K. contributed equally to this work.
Int. J. Mol. Sci. 2021, 22(23), 13144; https://doi.org/10.3390/ijms222313144
Submission received: 6 October 2021 / Revised: 2 December 2021 / Accepted: 2 December 2021 / Published: 5 December 2021
(This article belongs to the Special Issue Multiple Myeloma: Focus on Molecular and Epigenetic Aspects)
Browse Figures
Review Reports Versions Notes

Abstract

Multiple myeloma (MM) is the second most common hematological malignancy, arising from terminally differentiated B cells, namely plasma cells. miRNAs are small non-coding RNAs that participate in the post-transcriptional regulation of gene expression. In this study, we investigated the role of nine miRNAs in MM. CD138+ plasma cells were selected from bone marrow aspirates from MM and smoldering MM (sMM) patients. Total RNA was extracted and in vitro polyadenylated. Next, first-strand cDNA synthesis was performed using an oligo-dT–adapter primer. For the relative quantification of the investigated miRNAs, an in-house real-time quantitative PCR (qPCR) assay was developed. A functional in silico analysis of the miRNAs was also performed. miR-16-5p and miR-155-5p expression was significantly lower in the CD138+ plasma cells of MM patients than in those of sMM patients. Furthermore, lower levels of miR-15a-5p, miR-16-5p, and miR-222-3p were observed in the CD138+ plasma cells of MM patients with osteolytic bone lesions, compared to those without. miR-125b-5p was also overexpressed in the CD138+ plasma cells of MM patients with bone disease that presented with skeletal-related events (SREs). Furthermore, lower levels of miR-223-3p were associated with significantly worse overall survival in MM patients. In conclusion, we propose a miRNA signature with putative clinical utility in MM.
Keywords: miRNA; small non-coding RNA (sncRNA); plasma cell dyscrasias; multiple myeloma bone disease (MMBD); post-transcriptional regulation; target mRNA; KEGG pathways; molecular biomarkers; prognosis; overall survival miRNA; small non-coding RNA (sncRNA); plasma cell dyscrasias; multiple myeloma bone disease (MMBD); post-transcriptional regulation; target mRNA; KEGG pathways; molecular biomarkers; prognosis; overall survival

Share and Cite

MDPI and ACS Style

Papanota, A.-M.; Karousi, P.; Kontos, C.K.; Artemaki, P.I.; Liacos, C.-I.; Papadimitriou, M.-A.; Bagratuni, T.; Eleutherakis-Papaiakovou, E.; Malandrakis, P.; Ntanasis-Stathopoulos, I.; et al. A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. Int. J. Mol. Sci. 2021, 22, 13144. https://doi.org/10.3390/ijms222313144

AMA Style

Papanota A-M, Karousi P, Kontos CK, Artemaki PI, Liacos C-I, Papadimitriou M-A, Bagratuni T, Eleutherakis-Papaiakovou E, Malandrakis P, Ntanasis-Stathopoulos I, et al. A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. International Journal of Molecular Sciences. 2021; 22(23):13144. https://doi.org/10.3390/ijms222313144

Chicago/Turabian Style

Papanota, Aristea-Maria, Paraskevi Karousi, Christos K. Kontos, Pinelopi I. Artemaki, Christine-Ivy Liacos, Maria-Alexandra Papadimitriou, Tina Bagratuni, Evangelos Eleutherakis-Papaiakovou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, and et al. 2021. "A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma" International Journal of Molecular Sciences 22, no. 23: 13144. https://doi.org/10.3390/ijms222313144

APA Style

Papanota, A.-M., Karousi, P., Kontos, C. K., Artemaki, P. I., Liacos, C.-I., Papadimitriou, M.-A., Bagratuni, T., Eleutherakis-Papaiakovou, E., Malandrakis, P., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Kastritis, E., Avgeris, M., Dimopoulos, M.-A., Scorilas, A., & Terpos, E. (2021). A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. International Journal of Molecular Sciences, 22(23), 13144. https://doi.org/10.3390/ijms222313144

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop